Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to
2017
Published on April 2011

Report Summary

Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Uveitis Therapeutics - Pipeline Assessment and Market
Forecasts to 2017'. The report is an essential source of information and analysis on the global uveitis market. The report identifies the
key trends shaping and driving the global uveitis market. The report also provides insights on the prevalent competitive landscape and
the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report
provides valuable insights on the pipeline products within the global uveitis sector. This report is built using data and information
sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData expects the global uveitis therapeutics market to grow at 26.4% annually for the next seven years, from $317m in 2010 to
reach $1.6 billion by 2017. This significant growth is primarily attributed to increasing therapeutic options for the treatment of uveitis.
In addition, the successful launch of some targeted therapies such as Luveniq (voclosporin), AIN457 and the approval of Humira may
significantly stimulate market growth in the near future. However, the complex etiology of the condition will continue to be a barrier for
market growth

Scope

The report provides information on the key drivers and challenges of the uveitis market. Its scope includes -
- Annualized global uveitis market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends.
Pipeline candidates fall under major therapeutic classes such as calcineurin inhibitor, interleukin inhibitor, tnf-' inhibitor, pkc inhibitor,
mtor inhibitor, plasminogen activator, immune regulation and so on.
- Analysis of the current and future competition in the global uveitis market. Key market players covered are Lux Biosciences,
Novartis, and Abbott Laboratories.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a
qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the
uveitis market.
- Analysis of key recent licensing and partnership agreements in uveitis market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by
identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global uveitis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to

Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 (From Slideshare) Page 1/8


impact the global uveitis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of
various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive
advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities
for consolidations, investments and strategic partnerships.
- What's the next big thing in the global uveitis market landscape' ' Identify, understand and capitalize.

Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Uveitis Therapeutics: Introduction 6
2.1 Overview 6
2.2 Etiology and Pathophysiology 7
2.3 Epidemiology 8
2.4 Symptoms 8
2.5 Diagnosis 8
2.5.1 Visual Acuity and External Examination: 8
2.5.2 Slit-lamp Examination: 8
2.5.3 Tonometry 8
2.5.4 Supplemental Examination: 9
2.6 Treatment and Management Pattern 9
2.7 GlobalData Pipeline Report Guidance 10
3 Uveitis Therapeutics: Market Characterization 11
3.1 Overview 11
3.2 Uveitis Therapeutics Market Size 11
3.3 Uveitis Therapeutics Market Size (2005-2010) ' Global 11
3.4 Uveitis Therapeutics Market Forecast (2010-2017) ' Global 12
3.5 Uveitis Therapeutics Market Size (2005-2010) 'US 13
3.6 Uveitis Therapeutics Market Forecast (2010-2017) ' US 14
3.7 Uveitis Therapeutics Market Size (2005-2010) ' France 15
3.8 Uveitis Therapeutics Market Forecast (2010-2017) ' France 16
3.9 Uveitis Therapeutics Market Size (2005-2010) ' Germany 17
3.10 Uveitis Therapeutics Market Forecast (2010-2017) ' Germany 18
3.11 Uveitis Therapeutics Market Size (2005-2010) ' Italy 19
3.12 Uveitis Therapeutics Market Forecast (2010-2017) ' Italy 20
3.13 Uveitis Therapeutics Market Size (2005-2010) ' Spain 21
3.14 Uveitis Therapeutics Market Forecast (2010-2017) ' Spain 22
3.15 Uveitis Therapeutics Market Size (2005-2010) ' UK 23
3.16 Uveitis Therapeutics Market Forecast (2010-2017) ' UK 24
3.17 Uveitis Therapeutics Market Size (2005-2010) ' Japan 25
3.18 Uveitis Therapeutics Market Forecast (2010-2017) ' Japan 26



3.19 Drivers and Barriers 27
3.19.1 Drivers for the Uveitis Therapeutics Market 27
3.19.2 Barriers for the Uveitis Therapeutics Market 27
3.20 Opportunity and Unmet needs 28
3.21 Key Takeaway 29
4 Uveitis Therapeutics Market ' Competitive Assessment 30
4.1 Overview 30
4.2 Strategic Competitor Assessment 30
4.3 Product Profile for the Major Marketed Products in Uveitis Therapeutics Market 31
4.3.1 Overview 31
4.3.2 Corticosteroids 31
4.3.3 Immunosuppressants 31
4.4 Key Takeaway 31
5 Uveitis Therapeutics: Pipeline Assessment 32
5.1 Overview 32
5.2 Strategic Pipeline Assessment 32
5.3 Pipeline by Phases of Development 32
5.3.1 Uveitis Therapeutics ' Regulatory Filed Products 32
5.3.2 Uveitis Therapeutics-Phase III Pipeline 33
5.3.3 Uveitis Therapeutics-Phase II Pipeline 33
5.3.4 Uveitis Therapeutics-Phase I Pipeline 33
5.3.5 Uveitis Therapeutics-Pre-Clinical Pipeline 33
5.4 Uveitis Therapeutics Market'Pipeline by Mechanism of Action. 34
5.5 Technology Trends Analytic Framework 35
5.6 Promising Drugs Under Clinical Development 36
5.7 Profile for Promising Drugs 37
5.7.1 Luveniq 37
5.7.2 AIN457 (secukinumab) 38
5.7.3 Humira 38
5.8 Key Takeaway 39
6 Uveitis Therapeutics:Clinical Trials Mapping 40
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 40
6.2 Clinical Trials by Phase 41
6.3 Clinical Trials by Trial Status 42
6.4 Prominent Sponsors 43
6.5 Top Ten Companies Participating in Therapeutics Clinical Trials 44
7 Uveitis Therapeutics:Strategic Assessment 45
7.1 Key Events Impacting the Future Market 45
7.2 Future Market Competition Scenario 45
8 Uveitis:Future Players 47
8.1 Introduction 47
8.2 Company Profiles 47
8.2.1 Lux Biosciences 47
8.2.2 Novartis 48
8.2.3 Abbott Laboratories 51
8.2.4 Allergan 53
8.3 Other Companies in Uveitis Therapeutics Market 56
9 Uveitis Therapeutics: Liscensing and Partnership Deals 57



10 Appendix 58
10.1 Market Definitions 58
10.2 Abbreviations 58
10.3 Methodology 58
10.3.1 Coverage 59
10.3.2 Secondary Research 59
10.3.3 Forecasting 59
10.3.4 Primary Research 61
10.3.5 Expert Panel Validation 62
10.4 Contact Us 62
10.5 Disclaimer 62
10.6 Bibliography 62

1.1 List of Tables

Table 1: Uveitis- Anatomical Classification 6
Table 2: Uveitis- Classification Based On Severity 6
Table 3: Uveitis Therapeutics Market, Global, Revenue ($m), 2005-2010 11
Table 4: Uveitis Therapeutics Market, Global, Forecast ($m), 2010-2017 12
Table 5: Uveitis Therapeutics Market, US, Revenue ($m), 2005-2010 13
Table 6: Uveitis Therapeutics Market, US, Forecast ($m), 2010-2017 14
Table 7: Uveitis Therapeutics Market, France, Revenue ($m), 2005-2010 15
Table 8: Uveitis Therapeutics Market, France, Forecast ($m), 2010-2017 16
Table 9: Uveitis Therapeutics Market, Germany, Revenue ($m), 2005-2010 17
Table 10: Uveitis Therapeutics Market, Germany, Forecast ($m), 2010-2017 18
Table 11: Uveitis Therapeutics Market, Italy, Revenue ($m), 2005-2010 19
Table 12: Uveitis Therapeutics Market, Italy, Forecast ($m), 2010-2017 20
Table 13: Uveitis Therapeutics Market, Spain, Revenue ($m), 2005-2010 21
Table 14: Uveitis Therapeutics Market, Spain, Forecast ($m), 2010-2017 22
Table 15: Uveitis Therapeutics Market, UK, Revenue ($m), 2005-2010 23
Table 16: Uveitis Therapeutics Market, UK, Forecast ($m), 2010-2017 24
Table 17: Uveitis Therapeutics Market, Japan, Revenue ($m), 2005-2010 25
Table 18: Uveitis Therapeutics Market, Japan, Forecast ($m), 2010-2017 26
Table 19: Uveitis Therapeutics ' Regulatory Filed Products, 2011 32
Table 20: Uveitis Therapeutics ' Phase III Pipeline, 2011 33
Table 21: Uveitis Therapeutics ' Phase II Pipeline, 2011 33
Table 22: Uveitis Therapeutics ' Phase I Pipeline, 2011 33
Table 23: Uveitis Therapeutics ' Pre-Clinical Pipeline, 2011 33
Table 24: Uveitis Therapeutics ' Most Promising Drugs Under Clinical Development, 2011 36
Table 25: Uveitis Therapeutics ' Clinical Trials by Region, 2011 40
Table 26: Uveitis Therapeutics ' Clinical Trials by Phase of Development, 2011 41
Table 27: Uveitis Therapeutics ' Clinical Trials by Trial Status, 2011 42
Table 28: Uveitis Therapeutics ' Clinical Trials by Prominent Sponsors, 2011 44
Table 29: Uveitis Therapeutics ' Clinical Trials by Top Companies, 2011 44
Table 30: Lux Biosciences ' Ophthalmology Pipeline Products, 2010 48
Table 31: Lux Biosciences ' Ophthalmology Pipeline Products, 2010 48
Table 32: Novartis ' Ophthalmology Pipeline Products, 2010 49
Table 33: Novartis ' Ophthalmology Pipeline Products, 2010 49



Table 34: Novartis-Deals, 2009-2011 50
Table 35: Abbott ' Ophthalmology Pipeline Products, 2010 52
Table 36: Abbott Laboratories- Deals, 2009-2011 52
Table 37: Allergan-Ophthalmology Pipeline Products, 2010 55
Table 38: Allergan-Deals, 2010-2011 55
Table 39: Uveitis Therapeutics Market ' Future Players 56
Table 40: Uveitis Therapeutics, Global, Deals, 2009-2011 57

1.2 List of Figures

Figure 1: Etiology of Uveitis 7
Figure 2: Uveitis - Treatment and Management Pattern 9
Figure 3: Uveitis Therapeutics Market, Global, Revenue ($m), 2005-2010 11
Figure 4: Uveitis Therapeutics Market, Global, Forecast ($m), 2010-2017 12
Figure 5: Uveitis Therapeutics Market, US, Revenue ($m), 2005-2010 13
Figure 6: Uveitis Therapeutics Market, US, Forecast ($m), 2010-2017 14
Figure 7: Uveitis Therapeutics Market, France, Revenue ($m), 2005-2010 15
Figure 8: Uveitis Therapeutics Market, France, Forecast ($m), 2010-2017 16
Figure 9: Uveitis Therapeutics Market, Germany, Revenue ($m), 2005-2010 17
Figure 10: Uveitis Therapeutics Market, Germany, Forecast ($m), 2010-2017 18
Figure 11: Uveitis Therapeutics Market, Italy, Revenue ($m), 2005-2010 19
Figure 12: Uveitis Therapeutics Market, Italy, Forecast ($m), 2010-2017 20
Figure 13: Uveitis Therapeutics Market, Spain, Revenue ($m), 2005-2010 21
Figure 14: Uveitis Therapeutics Market, Spain, Forecast ($m), 2010-2017 22
Figure 15: Uveitis Therapeutics Market, UK, Revenue ($m), 2005-2010 23
Figure 16: Uveitis Therapeutics Market, UK, Forecast ($m), 2010-2017 24
Figure 17: Uveitis Therapeutics Market, Japan, Revenue ($m), 2005-2010 25
Figure 18: Uveitis Therapeutics Market, Japan, Forecast ($m), 2010-2017 26
Figure 19: Opportunity and Unmet Need in the Uveitis Therapeutics Market 28
Figure 20: Uveitis Therapeutics ' Strategic Competitor Assessment, 2010 30
Figure 21: Uveitis Therapeutics ' Pipeline by Phase of Development, 2011 32
Figure 22: Uveitis Therapeutics ' Pipeline by Mechanism of Action, 2011 34
Figure 23: Uveitis Therapeutics Technology ' Trends Analytic Framework, 2011 35
Figure 24: Uveitis Therapeutics ' Technology Trends Analytic Framework ' Description, 2011 36
Figure 25: Luveniq-Clinical Trial Details 37
Figure 26: Humira-Clinical Trial Details 38
Figure 27: Uveitis Therapeutics ' Clinical Trials by Region, 2011 40
Figure 28: Uveitis Therapeutics ' Clinical Trials by Phase of Development, 2011 41
Figure 29: Uveitis Therapeutics' Clinical Trials by Trial Status, 2011 42
Figure 30: Uveitis Therapeutics ' Clinical Trials by Overall Sponsors, 2011 43
Figure 31: Uveitis Therapeutics ' Clinical Trials by Prominent Sponsors, 2011 43
Figure 32: Uveitis Therapeutics Market, Global, Clinical Trials by Top Companies, 2010 44
Figure 33: Uveitis Therapeutics Market, Drivers and Restraints 2010 45
Figure 34: Implications for Future Market Competition in the Uveitis Therapeutics Market, 2010 46
Figure 35: Uveitis Therapeutics Market ' Pipeline by Company, 2010 47
Figure 36: GlobalData Market Forecasting Model 61

Companies Mentioned



Lux Biosciences
Novartis
Abbott Laboratories
Allergan


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Recomendados

Recomendados

Mais conteúdo relacionado

Destaque

Destaque (19)

Mais de ReportLinker.com

Mais de ReportLinker.com (20)

Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017